文献速递造血干细胞移植与细胞治疗MDS 与骨髓增殖性肿瘤白血病

范可尼贫血转化MDS/急性白血病患者异基因造血干细胞移植的EBMT回顾性分析

Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of EBMT group.
PubMed 文献 · Am J Hematol · 2020-04-21

该EBMT回顾性分析纳入1999至2016年间74例范可尼贫血合并骨髓增生异常综合征、急性白血病或细胞遗传学异常并接受异基因造血干细胞移植的患者,5年总生存率和无事件生存率分别为42%和39%。

要点

  • FA转化患者allo-HSCT后5年OS为42%,EFS为39%,预后仍较差

核心结论

  • 该分析证实转化型FA患者移植后结局较差,并明确移植前达到完全缓解的重要性。
  • 对于新诊断的转化型FA患者,若已找到供者,应考虑移植前采用细胞减灭策略。

研究设计与样本

  • EBMT网络多中心回顾性分析,纳入1999至2016年接受allo-HSCT的74例FA患者。
  • 患者诊断包括骨髓增生异常综合征35例、急性白血病35例、细胞遗传学异常4例。
  • 主要分析变量包括诊断类型、移植前细胞减灭治疗及毒性、移植前疾病状态、供者类型和预处理方案。

主要发现

  • 5年总生存率为42%(30-53%),5年无事件生存率为39%(27-51%)。
  • 100天II-IV级急性GVHD累积发生率为38%(26-50%),5年慢性GVHD累积发生率为40%(28-52%)。
  • 5年非复发死亡率为40%(29-52%),复发率为21%(11-30%),所测变量均无显著影响。

关键数值与推荐

  • 100天II-IV级a-GVHD累积发生率为38%(26-50%),5年c-GVHD为40%(28-52%)。
  • 5年非复发死亡率为40%(29-52%),复发率为21%(11-30%)。

临床怎么用

  • 对转化型FA患者应尽可能在移植前达到完全缓解以改善生存。
  • 若已找到供者,可考虑移植前细胞减灭治疗,但需关注3-4级毒性。
  • 移植相关事件是主要死亡原因,需优化移植全程管理。

局限性

  • 回顾性分析,样本量较小(74例),可能存在选择偏倚。
  • 未报告其他变量对结局的显著影响,可能受样本量限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is curative for bone marrow failure in patients with Fanconi anemia (FA), but the presence of a malignant transformation is associated with a poor prognosis and the management of these patients is still challenging. We analyzed outcome of 74 FA patients with a diagnosis of myelodysplastic syndrome (n = 35), acute leukemia (n = 35) or with cytogenetic abnormalities (n = 4), who underwent allo-HSCT from 1999 to 2016 in EBMT network. Type of diagnosis, pre-HSCT cytoreductive therapies and related toxicities, disease status pre-HSCT, donor type, and conditioning regimen were considered as main variables potentially influencing outcome. The 5-year OS and EFS were 42% (30-53%) and 39% (27-51%), respectively. Patients transplanted in CR showed better OS compared with those transplanted in presence of an active malignant disease (OS:71%[48-95] vs 37% [24-50],P = .04), while none of the other variables considered had an impact. Twenty-two patients received pre-HSCT cytoreduction and 9/22 showed a grade 3-4 toxicity, without any lethal event or negative influence on survival after HSCT(OS:toxicity pre-HSCT 48% [20-75%] vs no-toxicity 51% [25-78%],P = .98). The cumulative incidence of day-100 grade II-IV a-GvHD and of 5-year c-GvHD were 38% (26-50%) and 40% (28-52%). Non-relapse-related mortality and incidence of relapse at 5-years were 40% (29-52%) and 21% (11-30%) respectively, without any significant impact of the tested variables. Causes of death were transplant-related events in most patients (34 out of the 42 deaths, 81%). This analysis confirms the poor outcome of transformed FA patients and identifies the importance of achieving CR pre-HSCT, suggesting that, in a newly diagnosed transformed FA patient, a cytoreductive approach pre-HSCT should be considered if a donor have been secured.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Giardino S, de Latour RP, Aljurf M, et al. Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of EBMT group. Am J Hematol. 2020. PMID: 32267023. doi:10.1002/ajh.25810

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。